174 related articles for article (PubMed ID: 35085003)
1. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline
Lundy J; McKay O; Croagh D; Ganju V
JCO Precis Oncol; 2022 Jan; 6():e2100437. PubMed ID: 35085003
[No Abstract] [Full Text] [Related]
2. [Olaparib and pancreatic cancer: A challenging Lesson].
Louvet C; Samalin E; Michel P
Bull Cancer; 2019 Sep; 106(9):715-716. PubMed ID: 31399206
[No Abstract] [Full Text] [Related]
3. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Kaufman B; Shapira-Frommer R; Schmutzler RK; Audeh MW; Friedlander M; Balmaña J; Mitchell G; Fried G; Stemmer SM; Hubert A; Rosengarten O; Steiner M; Loman N; Bowen K; Fielding A; Domchek SM
J Clin Oncol; 2015 Jan; 33(3):244-50. PubMed ID: 25366685
[TBL] [Abstract][Full Text] [Related]
4. Maintenance Olaparib for Germline
Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
[TBL] [Abstract][Full Text] [Related]
5. A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
Wang H; Mao C; Li N; Sun L; Zheng Y; Xu N
Medicine (Baltimore); 2019 Oct; 98(40):e17443. PubMed ID: 31577767
[TBL] [Abstract][Full Text] [Related]
6. Some subgroups might get less benefit from adjuvant olaparib trial in high-risk, HER2-negative and germline BRCA2 BRCA1- or BRCA2-mutated early breast cancer patients.
Altundag K
J BUON; 2021; 26(5):2202. PubMed ID: 34761636
[No Abstract] [Full Text] [Related]
7. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
Hilmi M; Neuzillet C
Bull Cancer; 2020 Oct; 107(10):961-962. PubMed ID: 32943226
[No Abstract] [Full Text] [Related]
8. A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial).
Teke ME; Saif A; Ryan CE; Lux SC; Hernandez JM; Reiss KA
Ann Surg Oncol; 2022 Sep; 29(9):5375-5376. PubMed ID: 35668307
[No Abstract] [Full Text] [Related]
9. Olaparib shows promise in multiple tumor types.
Cancer Discov; 2013 Jul; 3(7):OF5. PubMed ID: 23847380
[TBL] [Abstract][Full Text] [Related]
10. A new targeted treatment for patients with a germline
Verdaguer H; Acosta D; Macarulla T
Future Oncol; 2020 Nov; 16(33):2691-2700. PubMed ID: 32799562
[TBL] [Abstract][Full Text] [Related]
11. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
[TBL] [Abstract][Full Text] [Related]
12. Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.
Assaf I; Mans L; Sakr R; Verset G; Van Laethem JL
Eur J Cancer; 2021 Nov; 157():63-67. PubMed ID: 34487986
[TBL] [Abstract][Full Text] [Related]
13. Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
Copur MS; Gauchan D; Brussow K; Clark D; Ramaekers R
J Clin Oncol; 2015 Aug; 33(23):2582. PubMed ID: 26124479
[No Abstract] [Full Text] [Related]
14. Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation.
Zhao XS; Zhou J; Dong L; Zhang H; Ye YJ
Chin Med J (Engl); 2019 Dec; 132(24):3012-3014. PubMed ID: 31764178
[No Abstract] [Full Text] [Related]
15. Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Ma Y; He L; Huang Q; Zheng S; Zhang Z; Li H; Liu S
BMC Med Genet; 2018 Oct; 19(1):185. PubMed ID: 30333000
[TBL] [Abstract][Full Text] [Related]
16. It's About Time!
Tempero M
J Natl Compr Canc Netw; 2020 Feb; 18(2):115. PubMed ID: 32023523
[No Abstract] [Full Text] [Related]
17. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Li M; Mou Y; Hou S; Cao D; Li A
Medicine (Baltimore); 2018 Nov; 97(45):e13113. PubMed ID: 30407325
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Wu B; Shi L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1528-1536. PubMed ID: 33152708
[TBL] [Abstract][Full Text] [Related]
19. Olaparib Approved for Metastatic Pancreatic Cancer.
Aschenbrenner DS
Am J Nurs; 2020 Apr; 120(4):22-23. PubMed ID: 32218041
[No Abstract] [Full Text] [Related]
20. An evaluation of olaparib for the treatment of pancreatic cancer.
Vaishampayan UN
Expert Opin Pharmacother; 2021 Mar; 22(4):521-526. PubMed ID: 33094666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
